Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Prepaid Assets (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Prepaid Assets for 16 consecutive years, with $3.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Prepaid Assets fell 3.7% to $3.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.3 million, a 3.7% decrease, with the full-year FY2024 number at $2.9 million, down 26.45% from a year prior.
  • Prepaid Assets was $3.3 million for Q3 2025 at Harvard Bioscience, down from $3.3 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $5.8 million in Q3 2021 to a low of $2.9 million in Q4 2024.
  • A 5-year average of $4.3 million and a median of $4.3 million in 2021 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: soared 45.73% in 2021, then plummeted 31.18% in 2025.
  • Harvard Bioscience's Prepaid Assets stood at $4.3 million in 2021, then fell by 20.02% to $3.5 million in 2022, then grew by 13.48% to $3.9 million in 2023, then dropped by 26.45% to $2.9 million in 2024, then rose by 13.01% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Prepaid Assets are $3.3 million (Q3 2025), $3.3 million (Q2 2025), and $3.1 million (Q1 2025).